Bogemann M, Shore ND, Smith MR, Tammela TLJ, et al. Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]. Eur Urol 2022 Dec 14:S0302-2838(22)02837-8. doi: 10.1016/j.eururo.2022.
PMID: 36526492